ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Budapest, Budapest

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Neoplasm Metastasis

Non-Small-Cell Lung Cancer trials near Budapest, Budapest, HUN:

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Budapest, Hungary and 83 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Budapest, Hungary and 210 other locations

Locations recently updated

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: JDQ443
Drug: docetaxel

Phase 3

Novartis
Novartis

Budapest, Hungary and 52 other locations

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC)....

Active, not recruiting
Metastatic Nonsquamous Non-Small Cell Lung Cancer
Metastatic Squamous Non-Small Cell Lung Cancer
Drug: Placebo
Drug: Paclitaxel

Phase 3

Incyte
Incyte

Budapest, Hungary and 140 other locations

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Durvalumab
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Budapest, Hungary and 230 other locations

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), ...

Enrolling
Non-small Cell Lung Cancer
Drug: Pemetrexed
Biological: HER3-DXd

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Budapest, Hungary and 29 other locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Budapest, Hungary and 254 other locations

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demon...

Active, not recruiting
Non-small Cell Lung Cancer
Lung Cancer
Drug: Bevacizumab
Drug: Carboplatin

Phase 3

Prestige Biopharma

Törökbálint, Hungary and 17 other locations

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non...

Active, not recruiting
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Drug: Erlotinib 150/100 mg
Drug: AZD9291 80 mg/40 mg + placebo

Phase 3

AstraZeneca
AstraZeneca

Tatabánya, Hungary and 169 other locations

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC)....

Enrolling
Non Small Cell Lung Cancer
Drug: IPH5201 + durvalumab + standard chemotherapy

Phase 2

Innate Pharma

Budapest, Hungary and 29 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems